GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grapefruit USA Inc (OTCPK:GPFT) » Definitions » Debt-to-EBITDA

Grapefruit USA (Grapefruit USA) Debt-to-EBITDA : -11.58 (As of Sep. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Grapefruit USA Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Grapefruit USA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $4.95 Mil. Grapefruit USA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Grapefruit USA's annualized EBITDA for the quarter that ended in Sep. 2023 was $-0.43 Mil. Grapefruit USA's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -11.57.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Grapefruit USA's Debt-to-EBITDA or its related term are showing as below:

GPFT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -46.3   Med: -0.29   Max: 0.29
Current: -46.3

During the past 13 years, the highest Debt-to-EBITDA Ratio of Grapefruit USA was 0.29. The lowest was -46.30. And the median was -0.29.

GPFT's Debt-to-EBITDA is ranked worse than
100% of 660 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs GPFT: -46.30

Grapefruit USA Debt-to-EBITDA Historical Data

The historical data trend for Grapefruit USA's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grapefruit USA Debt-to-EBITDA Chart

Grapefruit USA Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 -0.29 -0.80 -23.68 -2.61

Grapefruit USA Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.39 -75.85 -1.47 -23.17 -11.58

Competitive Comparison of Grapefruit USA's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Grapefruit USA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grapefruit USA's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grapefruit USA's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Grapefruit USA's Debt-to-EBITDA falls into.



Grapefruit USA Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Grapefruit USA's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.703 + 0.927) / -2.156
=-2.61

Grapefruit USA's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.954 + 0) / -0.428
=-11.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.


Grapefruit USA  (OTCPK:GPFT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Grapefruit USA Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Grapefruit USA's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Grapefruit USA (Grapefruit USA) Business Description

Traded in Other Exchanges
N/A
Address
10866 Wilshire Boulevard, Suite 225, Los Angeles, CA, USA, 90024
Grapefruit USA Inc manufactures and distributes cannabis-based products. Its extraction lab produces high-quality distillate or Honey Oil from trim that Grapefruit sources through its Distribution arm. The company is a premier licensed Distributor of all things cannabis throughout the State of California. It serves licensed Medicinal and Recreational Dispensaries. Its patented product is Hourglass Cream. Grapefruit owns and operates a California-licensed cannabis extraction laboratory and wholesale distribution facility in the Coachillin' Canna-Business Park near Palm Springs, California.
Executives
Bradley J Yourist director, 10 percent owner, officer: Chairman and CEO 10866 WILSHIRE BLVD, #225, LOS ANGELES CA 90024
Daniel J. Yourist director, 10 percent owner, officer: Board of Directors and COO 10866 WILSHIRE BLVD, SUITE 225, LOS ANGELES CA 90024
Dane Medley director, officer: CEO/Chairman 10553 CAMARILLO STREET, TOLUCA LAKE CA 91602
Emilio Xavier Aguilera director, officer: Chief Financial Officer 16827 HALSEY STREET, GRANADA HILLS CA 91344
Dean Janes officer: CHIEF EXECUTIVE OFFICER 3200 W. VALHALLA DRIVE, BURBANK CA 91505
Christopher Sohn director, officer: President and COO 3200 W. VALHALLA DRIVE, BURBANK CA 91505
Xavier Aguilera director, officer: CFO/Treasurer,Exec.V.P.& Secy 3200 W. VALHALLA DRIVE, BURBANK CA 91505
Michele Janes officer: Vice President of Admin. 3200 W. VALHALLA DRIVE, BURBANK CA 91505

Grapefruit USA (Grapefruit USA) Headlines

From GuruFocus

Grapefruit USA, Inc. Issues Update on Proposed Strategic Acquisition

By GuruFocusNews GuruFocusNews 05-09-2022

Grapefruit's 'Summit Boys' Brand Goes Mobile on Blitzdirect.com

By GuruFocusNews GuruFocusNews 04-04-2022